Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin to reduce myocardial infarct size after acute STEMI
MOH_2021-11-10_010104Phase 2Not yet recruiting
- Sponsor
- ד"ר פרננדו צ'רנומורדיק
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in myocardial infarction (MI) (2 arms), sponsored by ד"ר פרננדו צ'רנומורדיק. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2021-11-10_010104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-10_010104.